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Premature Termination Mutations in FBN1: Distinct Effects on Differential
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Marfan syndrome (MFS) and other type 1 fibrillinopathies result from mutations in the FBN1 gene, which encodes
the connective-tissue microfibrillar protein fibrillin 1. Attempts at correlating genotype with phenotype have sug-
gested considerable heterogeneity. To define the subtype of fibrillinopathy caused by premature termination codon
(PTC) mutations, we integrate genotype information and mRNA expression levels with clinical and biochemical
phenotypes. By screening the entire FBN1 gene for mutations, we identified 34 probands with PTC mutations.
With the exception of two recurrent mutations, these nonsense and frameshift mutations are unique and span the
entire FBN1 gene, from IVS2 to IVS63. Allele-specific reverse-transcriptase polymerase chain reaction analyses
revealed differential allelic expression in all studied samples, with variable reduction of the mutant transcript.
Fibrillin protein synthesis and deposition into the extracellular matrix were studied by pulse-chase analysis of
cultured fibroblasts. In the majority of PTC samples, synthesis of normal-sized fibrillin protein was ∼50% of control
levels, but matrix deposition was disproportionately decreased. Probands and mutation-positive relatives were
clinically evaluated by means of a standardized protocol. Only 71% (22/31) of probands and 58% (14/24) of the
mutation-positive family members met current clinical diagnostic criteria for MFS. When compared with our
previously reported study group of 44 individuals with FBN1 cysteine substitutions, the PTC group showed sta-
tistically significant differences in the frequency of individual signs, especially in the ocular manifestations. Whereas
large-joint hypermobility was more common, lens dislocation and retinal detachment were distinctly less common
in the PTC group. We conclude that PTC mutations have a major impact on the pathogenesis of type 1 fibrillinopa-
thies and convey a distinct biochemical, clinical, and prognostic profile.
Introduction
Fibrillinopathies are characterized by defects in fibrillin
proteins. Fibrillin 1 is the predominant component of
extracellular matrix microfibrils (Sakai et al. 1986;
Aoyama et al. 1995). The 350-kD glycoprotein fibrillin
1 is produced as a larger form (profibrillin 1), which
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is proteolytically processed at its unique N- and C-
terminal domains before or during secretion from the
cell (Reinhardt et al. 1996; Lonnqvist et al. 1998).
Fibrillin 1 has a modular structure, with 47 repeats
of six-cysteine epidermal-growth-factor (EGF)–like re-
peats, 43 of which are of the calcium-binding type
(cbEGF) (Handford et al. 2000). It also contains several
eight-cysteine motifs, which bear homology to motifs
found in the latent transforming growth factor b bind-
ing proteins (LTBP family) (Saharinen and Keski-Oja
2000). Abnormalities in fibrillin 1 cause a spectrum of
connective-tissue phenotypes, including Marfan syn-
drome (MFS [MIM #154700]), a pleiotropic disorder
with autosomal dominant inheritance (reviewed by
Robinson and Godfrey 2000). MFS affects ∼1 in
10,000 individuals and is diagnosed mainly on clinical
grounds (Pyeritz 2000; Schrijver et al. 2001). Recently
revised diagnostic criteria take into account skeletal,
cardiovascular, and ocular manifestations; signs and
symptoms in the lungs, dural sac, and skin; and family
history (De Paepe et al. 1996). In addition, mutations
in the FBN1 gene that are known to cause MFS can
be included as major diagnostic criteria.
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FBN1 (MIM 134797) is a large gene, located in chro-
mosome band 15q21.1, that spans 1235 kb (extending
approximately from nt 45185000 to nt 44950000 in
the UCSC Human Genome Project Working Draft se-
quence). FBN1 contains 65 coding exons and 3 alter-
natively spliced 5′ untranslated exons (Pereira et al.
1993; Biery et al. 1999). Three types of mutations,
which have been identified throughout the gene, lead to
a disease phenotype (Collod-Beroud et al. 1998; Rob-
inson and Godfrey 2000). Missense mutations that sub-
stitute residues important for calcium binding and for
the structural integrity of EGF-like repeats constitute
30%–40% of FBN1 mutations identified. They include
substitutions of cysteine residues or any of the four
amino acids that offer ligands for calcium binding (Dietz
et al. 1991; Tynan et al. 1993; Halliday et al. 1999;
Schrijver et al. 1999). A second category is represented
by in-frame deletions due to exon-skipping/splice-site
mutations (Liu et al. 1996) or genomic deletions (Kain-
ulainen et al. 1992; Liu et al. 2001). The third mutation
type, accounting for ∼25% of FBN1mutations, consists
of frameshift or nonsense mutations leading to pre-
mature termination codons (PTC) (Dietz et al. 1993a;
Tynan et al. 1993; Nijbroek et al. 1995; Karttunen et
al. 1998; Beroud et al. 2000; Loeys et al. 2001; Pepe et
al. 2001; Tiecke et al. 2001).
Genotype-phenotype correlations in the type 1 fibril-
linopathies—disorders caused by FBN1 mutations—
have been complicated by the large number (1250) of
unique mutations reported, as well as by clinical heter-
ogeneity among individuals with the same mutation.
Some associations have emerged, however. Skipping of
exons 24–32 correlates with the most severe, neonatal
forms ofMFS (Liu et al. 1996; Putnam et al. 1996; Booms
et al. 1999). Severe manifestations are also associated
with multiexon deletions (Liu et al. 2001). Mutations
that change a cysteine residue or a residue that is crucial
for calcium binding in one of the cbEGF-like domains
usually cause classic MFS (Schrijver et al. 1999; Tiecke
et al. 2001). Milder forms of type 1 fibrillinopathy are
often seen in individuals who carry mutations that lead
to replacement of non-cysteine, non–calcium-binding
amino acids, although the degree of severity is variable
(Francke et al. 1995; Furthmayr and Francke 1997; Palz
et al. 2000).
In the present study, we report 19 novel premature
stop-codon mutations in FBN1. Together with 13
unique PTC mutations previously reported from our
laboratory (Tynan et al. 1993; Liu et al. 1997/1998)
and 2 spontaneous de novo recurrent mutations, we
have assembled data on 60 mutation-positive members
of 16 families, with the goal of correlating themutations
with mutant transcript levels, fibrillin protein pheno-
types, and clinical phenotypes. PTC mutations predict
the production of truncated fibrillin 1 monomers, which
can interfere with the assembly of normal monomers
into extracellular microfibrils. This postulated domi-
nant negative effect is, however, ameliorated by insta-
bility of the mutant mRNA transcripts that are pref-
erentially degraded by the nonsense-mediated mRNA
decay mechanism (Cheng and Maquat 1993; Dietz et
al. 1993a). We observed differential expression of FBN1
mRNA in all studied skin fibroblast cultures, with dras-
tic reduction of the mutant mRNA. In the majority of
cultures, synthesis of normal-sized fibrillin protein was
reduced to50% of normal, but matrix deposition was
disproportionately lower. Comparison and quantitative
analysis revealed significant differences between the
clinical manifestations in 34 probands and 26 PTC mu-
tation–positive relatives, on one hand, and a group of
25 probands and 19 mutation-positive relatives with
FBN1 cysteine substitutions, on the other. The PTC sub-
group of type 1 fibrillinopathy has more-striking skel-
etal features and large-joint laxity, coupled with a much
lower risk of serious ocular manifestations. Ascending
aortic dissections were more common in the PTC group,
whereas ascending aortic aneurysms presented the pre-
vailing indication for aortic replacement surgery in the
cysteine substitution group. This is the first report of a
large-scale comparison of fibrillinopathy subgroups, de-
fined by FBN1 mutation type, that were systematically
evaluated for the same clinical and biochemical features
within a single MFS research center.
Subjects, Material, and Methods
Participants
Study participants were examined in the Center for
Marfan Syndrome and Related Connective Tissue Dis-
orders at Stanford Medical Center and were recruited
to the study under an institutional-review-board ap-
proved protocol and informed consent. Physical exam-
ination included the parameters set forth in the Ghent
Diagnostic Criteria (De Paepe et al. 1996). Patients were
evaluated for dolichostenomelia by measurement of the
upper-to-lower body-segment ratio (0.85 in dolicho-
stenomelia) and armspan-to-height ratio (11.05 in dol-
ichostenomelia). Arachnodactyly was assessed by hand
measurements. Facial features, height and width of the
palate, dental crowding, pectus deformities, scoliosis,
contractures, hypermobility of the large and small joints,
and the presence of striae atrophicae were scored by use
of standardized criteria. Ophthalmology, echocardio-
graphy, cardiology, and orthopedics reports were re-
viewed, and patients were asked to disclose any history
of hernias or pneumothorax. No imaging was performed
to look for dural ectasia or protrusio acetabuli. Skin
biopsies, buccal swabs (Cytobrush Plus Cell Collector;
Medscand Medical AB), and peripheral blood samples
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were obtained. Control samples were from unaffected
volunteers.
Detailed clinical information was obtained on 34 pro-
bands and 26 PTC mutation–positive family members.
Two probands were lost to follow up, and four died
within the 10-year study period. To compare the relative
frequency of connective-tissue manifestations, the PTC
group was compared with a previously published col-
lection of individuals with cysteine substitutions in FBN1
(Schrijver et al. 1999). Ascertainment through cardiovas-
cular surgery was similar in both groups: 10/34 (29%)
for the PTC group and 5/25 (20%) for the cysteine group.
The remainder were recruited from the outpatient clinic
population by use of identical criteria.
PCR and DNA Sequencing
DNA and RNA were extracted from fresh leukocytes
or cultured fibroblasts by standard procedures and from
buccal epithelial cells as described by Richards et al.
(1997). FBN1 mutations were initially detected by RT-
PCR and SSCA, followed by sequencing (Tynan et al.
1993). For genomic analysis of the FBN1 gene, DNA
was amplified with intronic primers flanking each of the
65 exons (Nijbroek et al. 1995; Liu et al. 1997/1998).
If a heteroduplex pattern was detected by mutation de-
tection enhancement (MDE) gel electrophoresis or de-
naturing high performance liquid chromatography
(DHPLC) (Liu et al. 1997/1998), the PCR product was
subsequently sequenced on an ABI 377 sequencer, as
described by Schrijver et al. (1999). All FBN1mutations
were confirmed on an independently obtained sample,
such as a blood or buccal smear from the proband and/
or from affected relatives.
RT-PCR Analysis of Allele-Specific Transcript Levels
To compare levels of mutant relative to normal FBN1
transcripts, a combination of 32P-labeled PCR and re-
striction digestion was employed. Total RNA was ex-
tracted and treated with RNase-free DNase (Ambion).
After incubation at 37C for 20 min, the sample was
heated to 70C for 10 min, to destroy the DNase. Re-
verse transcription of total RNA was performed using
Superscript II (Gibco BRL). The products of the first
strand reaction were amplified using paired primers, as
reported elsewhere (Tynan et al. 1993). Thermal cycling
was performed as described elsewhere (Schrijver et al.
1999). After 20 or 21 cycles, one of each primer pair
labeled with 32P-gATP (Amersham) was added to each
reaction, followed by one more cycle and a final exten-
sion step of 10 min at 72C. Labeled PCRs were per-
formed with AmpliTaq Gold DNA polymerase (Perkin
Elmer). Cold PCRs were run in parallel but were ex-
tended to 35 cycles.
Restriction digestion was performed, on both labeled
and unlabeled PCR products, with an enzyme that dis-
tinguishes the mutant from the normal allele (table 1).
Unlabeled digests were electrophoresed on a 2% aga-
rose/2% NuSieve (Bio Whittaker Molecular Probes) gel,
whereas labeled digestion products were separated by
electrophoresis on 8% polyacrylamide gels. Gels were
dried and then autoradiographed. Quantitation of the
labeled cDNA products was performed by phosphor-
imaging (Molecular Dynamics). The levels of intensity
of digested and undigested bands were quantitated, with
expression of the normal allele considered to be 100%.
Genomic DNA from each proband was amplified with
exon-specific primers (Nijbroek et al. 1995) and was
digested as a control for digestion efficiency. The thermal
cycling for genomic controls was modified to denatur-
ation at 95C and to 45 s for each annealing step.
Allele-specific transcript levels of samples FB773,
FB798, FB821, FB860, FB969, FB997, FB1058,
FB1103, FB1162, and FB1220 were also assessed by
RT-PCR of two FBN1 single-nucleotide polymorphisms
(SNPs): C8931T, in the 3′ UTR (Tynan et al. 1993; Hew-
ett et al. 1994), and T1875C, in exon 15 (Hayward et
al. 1994). RT-PCR, RsaI digestion, and electrophoresis
were performed as described by Schrijver et al. (1999).
The two allelic transcripts were distinguished by SSCA
and silver staining, according to the protocol provided
by the manufacturer (BioRad), and were subsequently
quantified by scanning densitometry.
Fibrillin 1 Pulse-Chase Analysis
Fibrillin protein was metabolically labeled with 35S-
cysteine (“pulse”) for 30 min and either (a) harvested
immediately or (b) harvested after 8-h or 20-h incuba-
tions with unlabeled cysteine (“chase”). The quantitative
assay of fibrillin in the soluble intracellular and insoluble
extracellular fractions was performed as described else-
where (Brenn et al. 1996; Schrijver et al. 1999). After
protein separation on SDS-PAGE, the gels were dried
and exposed to a phosphor screen. Protein bands were
examined on a phosphorimager (Molecular Dynamics).
Fibrillin 1 was identified in its characteristic position and
was subsequently quantified (Aoyama et al. 1994; Brenn
et al. 1996). Samples were assigned to biosynthetic
groups I–IV, as described by Aoyama et al. (1994). In
that original article, we also described a group V that
is indistinguishable from the normal control; none of the
samples with PTC mutations were assigned to group V.
Results
PTC Mutations in the FBN1 Gene
Thirty-four unrelated probands with mutations lead-
ing to PTCs were identified by RT-PCR/single-strand
conformation analysis of overlapping segments of the
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Figure 1 Effect of splice-site mutation 80511GrA on the
FBN1 transcript. Direct sequencing of RT-PCR products from fi-
broblast of a normal control (top) and proband FB1477 with
80511GrA (bottom) reveals skipping of exon 63. This event leads
to deletion of the two most C-terminal cbEGF-like domains and to a
frameshift, resulting in premature termination of translation at amino
acid position 2751 in exon 65 in the unique C-terminal region.
FBN1 coding region or by amplification of all 65 FBN1
exons followed by MDE or denaturing HPLC hetero-
duplex screening (table 1). On the genomic level, the
mutations were precisely defined by sequencing of PCR
products directly or after subcloning. Thirteenmutations
discovered by DHPLC have been described elsewhere,
in a methods article that did not include any clinical
data (Liu et al. 1997/1998). Twenty PTC mutations are
reported in the present study for the first time. The mu-
tations span the FBN1 gene from IVS2 to IVS63, with
a rather even distribution. They affect all domain types
of the fibrillin 1 protein except for the unique region
located at the carboxyl terminus (table 1). All of the
34 mutations are unique, except for one recurrence
(2581CrT) in our sample and one recurrence of a pre-
viously reported 2471GrA mutation that causes skip-
ping of exon 2 (Dietz et al. 1993a; Halliday et al. 1999;
Guo et al. 2001; Loeys et al. 2001). Both recurring mu-
tations involve CrT transitions on the sense or antisense
strand at a CpG dinucleotide. Of the 13 unique nonsense
mutations due to single-nucleotide substitutions that
change an amino acid codon to a stop codon, 5 are CGA
(R) to TGA (X) mutations at CpG hotspots (table 1).
The 20 frameshift mutations include 7 single-nucleotide
deletions, 4 single-nucleotide insertions, 4 multinucleo-
tide deletions, 2 complex insertion/deletions, and 1 five-
nucleotide tandem duplication. In addition, two splice-
site mutations (2471GrA and 80511GrA) result in
skipping of exons 2 and 63, respectively. These are two
of the three out-of-frame exons in the FBN1 gene and,
therefore, deletion of these exons leads to frameshifts
(fig. 1).
Assessment of Allele-Specific FBN1 Transcript Levels
Since relative levels of mutant RNA were estimated
by three different methods and on more than one oc-
casion, the combined results were placed into categories
defined by brackets (table 1). Representative samples in
which the FBN1 mutation either generated a new re-
striction site or abolished one (FB860, FB969, FB939,
FB938, FB1305, FB1162, FB1058, and FB1324) were
evaluated by restriction digestion of radioactively la-
beled and unlabeled RT-PCR products from cultured
skin fibroblasts. Labeled and unlabeled PCR products
of the corresponding genomic regions were used as con-
trols. In all cases studied, the mutant transcripts were
reduced; the degree of reduction was expressed as non-
detectable/severely reduced (!10%) (level 3), markedly
reduced (10%–29%) (level 2), and slightly reduced
(30%–50%) (level 1) (table 1 and fig. 2).
In FB1058, the 3778GrT (E1260X) nonsense mu-
tation in exon 30 destroys a BpmI site. Fragments rep-
resentative of both the normal (289 bp and 202 bp) and
mutant alleles (491 bp) were observed (fig. 2, top). A
normal control RNA sample was reverse transcribed,
amplified, and digested in parallel. Although the 491-
bp full-length PCR amplicon was still faintly visible, it
was much less intense, when visualized on an agarose
gel, than the corresponding band in the FB1058 sample.
Labeled RT-PCR with subsequent BpmI digestion re-
sulted in an abundance of the 289-bp fragment and a
disproportionately small amount of the mutant 491-bp
fragment upon phosphorimaging. BpmI digestion of la-
beled genomic PCR products resulted in bands repre-
sentative of both mutant (491 bp) and normal (289 bp
 202 bp) alleles. These were present at an ∼1:1 ratio
(data not shown).
FB1324 is heterozygous for the frameshift mutation
6185insA in exon 50 (table 1 and fig. 2, middle). MseI
digestion of unlabeled and radioactively labeled RT-PCR
products allowed the visualization of only the original
423-bp PCR amplicon, reflecting the normal allele. The
345-bp band expected to be generated from the mutant
allele was not detectable. Digestion of unlabeled as well
as 32P-labeled genomic PCR amplicons produced a 250-
bp band (normal allele) and a 180-bp fragment (mutant
allele). Thus, failure to detect the mutant allele in cDNA
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Figure 2 Detection of allele-specific transcripts. Top, Mutation
3778GrT abolishes a BpmI site. Top left, Unlabeled RT-PCR of a
region spanning nts 3506–3996 of the FBN1 cDNA sequence, digested
with BpmI. Digestion products from both the proband (P) and a nor-
mal control (C) are shown. Top right, 32P-labeled RT-PCR and diges-
tion with BpmI of proband cDNA. Both digested (D) and undigested
(U) products are shown. Middle, Mutation 6185insA generates new
MseI site. Middle left, 32P-labeled RT-PCR and digestion with MseI.
Undigested (U) and digested (D) samples from proband are shown.
Middle right, Genomic PCR of exon 50 from proband and digestion
with MseI. Bottom, Mutation 7240CrT abolishes BslI site. Bottom
left, 32P labeled RT-PCR and digestion with BslI. Undigested (U) and
digested (D) samples from proband are shown. Bottom right, 32P la-
beled genomic PCR of exon 58 from proband and digestion with BslI.
Figure 3 Comparison of transcript levels for FBN1 alleles dis-
tinguished by the C6236T RsaI polymorphism in the 3′ UTR. All
samples are from heterozygotes. RT-PCR products from fibroblast
RNA samples were digested withRsaI and electrophoresed on an SSCA
gel under denaturing conditions. The band labeled “T” represents the
uncut T allele, the two bands labeled “C” represent the cut C allele,
and the band marked by an asterisk (*) is constant. Samples 3 and
12 are normal controls. Unequal transcript levels are evident in four
samples with PTC mutations. Lane 1, FB 1058 (E1260X); lane 4, FB
1103 (L1161X); lane 6, FB773 (R1192X); and lane 11, FB997
(R1523X). Samples 1 and 11 reveal predominant transcripts with the
C allele, whereas in samples 4 and 6 only the T allele is detectable.
In contrast, the sample in lane 2 is from FB774, with a genomic deletion
of exons 42 and 43 (Liu et al. 2001), and the one in lane 8 is from
FB808, with the cysteine substitution C637R (Schrijver et al. 1999).
Both of these samples, as well as the ones in lanes 5, 9, and 10,
generated the normal pattern of fragments, indicating equal transcripts
of both alleles. Lane 7 shows slight skewing towards the C allele. For
samples 5, 7, 9, and 10, no FBN1 mutations have been identified as
yet.
was not a result of enzyme inefficiency. In the genomic
digest, however, the mutant 180-bp fragment is consid-
erably weaker than the 250-bp undigested normal allele,
probably because of formation of heteroduplex mole-
cules that are resistant to MseI digestion. Therefore, a
small amount of mutant cDNA would not have been
detected in this assay.
Unlabeled and labeled cDNA PCR products from
FB938, known to carry a 7240CrT (R2414X) nonsense
mutation in exon 58, were digested with BslI (fig. 2,
bottom). The restriction site is only present in the normal
sequence. After agarose gel electrophoresis, bands of
both the normal (483 bp) and mutant (587 bp) tran-
scripts were identified. cDNA from a normal control was
also amplified and fully digested with BslI. Phosphor-
imaging quantitation of the relative intensities of the
bands representing the normal versus the mutant tran-
script in FB938 indicated mutant allele expression at
36%–45% of the normal allele. This may be an over-
estimate, however, because heteroduplex molecules
would be included in the “mutant” undigested band.
To obtain an independent estimate of allele-specific
transcript levels, samples FB773, FB798, FB821, FB860,
FB969, FB997, FB1058, FB1103, FB1162, and FB1220
were also studied by RT-PCR of two regions with com-
mon FBN1 SNPs. C8931T, in the 3′ UTR, has a het-
erozygote frequency of 47% (Tynan et al. 1993; Hewett
et al. 1994) and T1875C, in exon 15, has a heterozy-
gosity level of 30% (Hayward et al. 1994). Nine studied
samples were heterozygous for the RsaI polymorphism
in the 3′ UTR, and seven were heterozygous for the SNP
in exon 15. Representative results for the 3′ UTR SNP
are shown in figure 3. The level of unequal expression
was designated by one of three degrees of severity de-
fined above (i.e., level 3p only one allele detected; level
2 p marked difference; and level 1p slight difference)
(table 1).
Of the 14 samples with PTC mutations, 8 were in-
formative with two of the three assays used, 5 were
informative with one, and 1 was informative with all
three. In all 14 samples, the mutant transcript levels were
reduced compared with levels in the normal allele, or,
in phase-unknown cases, one of the transcript levels was
lower than the other. The combined results were ex-
pressed as one of three categories of reduction (table 1).
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Figure 4 Reduced fibrillin 1 synthesis and deposition in a proband with a premature termination mutation in the FBN1 gene. Radioactively
labeled fibrillin (arrows) is visualized after pulse-chase analysis of cultured skin fibroblasts from a normal control subject and FB1533
(5240insACACT, leading to a PTC in exon 46). After a 30-min pulse with 35S-cysteine, FB1533 demonstrates reduced synthesis of normal-sized
fibrillin (34% of the normal control sample). Protein deposition is assessed after a 20-h “chase” period in which labeled fibrillin is secreted
from the cells and accumulates in the extracellular matrix. Matrix deposition is reduced in FB1533. At 20% of the normal control level, it is
disproportionately low, suggesting a dominant-negative mechanism. These results place FB1533 into protein group II (Aoyama et al. 1994).
Pulse-Chase Studies of Fibrillin Protein
Pulse-chase analysis, a quantitative assay for moni-
toring protein synthesis in the cell and deposition of
newly synthesized protein in the extracellular connective
tissue, enables subdivision of patients with type 1 fi-
brillinopathies into four different pathologic phenotypic
groups (see table 1 of Aoyama et al. 1994). The assay
was performed on 28 fibroblast cultures with PTC mu-
tations (table 1 and fig. 4). The vast majority (25/28) of
these samples were assigned to protein group I or II,
both of which are characterized by reduced synthesis of
normal fibrillin molecules (!70% of normal control val-
ues). This result is consistent with the presence of a single
wild-type FBN1 allele in these cells. In the 21 group II
samples, there was disproportionate reduction of extra-
cellular matrix deposition (!35% of control values) of
the newly synthesized full-length fibrillin molecules. The
four samples in protein group I (characterized by re-
duced fibrillin synthesis and proportionate reduction of
extracellular matrix deposition at 35%–70% of control
values) carry mutations that lead to PTC in exons 8, 15,
28, and 50. Mutant transcript levels, studied in only one
of the four group I samples (FB969), were undetectable.
In this study, which was performed blindly, only 3/
28 samples showed apparently normal levels of fi-
brillin synthesis: two in group III (with moderately
reduced deposition) and one in group IV (with se-
verely reduced deposition). Normal fibrillin protein
synthesis has also been reported for the frameshift
mutation 4365delCT (Halliday et al. 1999). It is pos-
sible that skipping of the PTC-containing exon has
generated an apparently normal-sized mutant protein
or that the normal FBN1 allele is somehow upregu-
lated in these cases. Remarkably, none of our samples
were found to have normal fibrillin synthesis and nor-
mal deposition (i.e., group V), which supports the sen-
sitivity of the pulse-chase assay for the detection of
molecular pathology in type 1 fibrillinopathies, as well
as the specificity of the group assignments (table 1)
(Brenn et al. 1996).
PTC-Associated Clinical Phenotypes
Detailed clinical information on 34 probands and 26
mutation-positive family members is listed in table 2. Of
the individuals with a PTC mutation, dilatation of the
ascending aorta was present in 44/57 individuals (77%)
and required surgical aortic root replacement in 26/60
individuals (43%). The average age at cardiovascular
surgery was 37 years, with a range of 22–59 years. Mi-
tral-valve prolapse (MVP), in 38/57 individuals (67%),
and mitral regurgitation (MR), in 35/53 individuals
(66%), were also common findings.
Ocular-system manifestations were distinctly less fre-
quent. Lens dislocation, or ectopia lentis (EL), was di-
agnosed in only 18/57 individuals who had received di-
lated eye examinations (32%). EL was bilateral in 15
and unilateral in 3 individuals. Of 10 families, 9 were
discordant for the presence of EL. Myopia was present
in 38/57 individuals (67%). Retinal detachment (RD)
was rare, having occurred in only 3/57 patients (5%).
Skeletal features were pronounced, often with exces-
sive height measurements. The vast majority of study
participants had pectus deformities, scoliosis, high and
narrow palate, joint hypermobility, and arachnodactyly.
Wrist and thumb signs were present in 29 subjects, out
of 50 who were evaluated for both features (58%). Al-
though skeletal features were common, only five patients
underwent surgical treatment, one for severe pectus de-
formity and four for scoliosis.
Cutaneous striae atrophicae (not associated with
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Figure 5 Frequency of connective-tissue clinical features in study participants with PTC mutations, compared with those with cysteine
substitutions (Schrijver et al. 1999). The percentage of all participants who are positive for the studied skeletal, ocular, cardiovascular, and
other phenotypes in each of the two groups is demonstrated along the Y-axis. Individual manifestations are listed along the X-axis. Blackened
columns represent PTC mutations, and shaded columns reflect cysteine substitutions. DCS p dolichostenomelia; PE/PC p pectus excavatum/
pectus carinatum; SCp scoliosis; H/NPp high/narrow palate; DCp dental crowding; CTRp contractures; HSJp hypermobile small joints;
HLJ p hypermobile large joints; WS p wrist sign; TSp thumb sign; ARDp arachnodactyly; ELp ectopia lentis; RDp retinal detachment;
AAA p ascending aortic aneurysm; AD p aortic dissection; ARR p aortic root replacement; MVP p mitral valve prolapse; MR p mitral
regurgitation; and PMT p pneumothorax. Differences for HLJ, EL, and RD were statistically significant.
weight change or pregnancy) were present in 47/57
(82%); inguinal, incisional, or umbilical hernias were
present in 17/57 (30%); and spontaneous pneumotho-
rax was reported in 8/58 (14%) of study subjects.
Genotype-Phenotype Correlations: Comparing PTC
to Cysteine Substitution Mutations
The phenotypic manifestations of the 60 study sub-
jects with PTC mutations were compared to those of the
44 previously reported individuals with FBN1 cysteine
substitutions (Schrijver et al. 1999), by x2 analysis with
1 df. These are the largest mutation-specific groups of
type 1 fibrillinopathies for which detailed phenotypic
data are available. Distinct differences between the two
groups were observed (fig. 5).
Most notably, EL was present in 36/42 (86%) infor-
mative individuals with cysteine substitutions but in only
18/57 (32%) of those with PTC mutations ( ).P ! .001
RD was also much more prevalent in the cysteine sub-
stitution group, at 9/39 (23%), versus 3/57 (5%) in the
PTC group ( ). For all ocular findings, the fractionP ! .01
of positives were very similar when probands and rel-
atives were considered separately. The observed differ-
ences cannot be accounted for by differences in age.
Skeletal system manifestations, in contrast, were more
pronounced in patients with PTCmutations. Large-joint
hypermobility was present in 42/50 (84%) individuals
in the group with PTC mutations and in 19/34 (56%)
individuals in the cysteine substitution group ( ).P ! .01
Scoliosis was associated with 42/57 (74%) of all PTC
mutations and with 20/36 (56%) of cysteine substitu-
tions, but this difference was not significant ( ).Pp .07
Aortic dissections appeared to be more common in the
premature termination group, occurring in 15/60 (25%)
patients, compared with 6/40 (15%) individuals in the
cysteine substitution group (P value not significant). As
expected, aortic dissection in both groups was more fre-
quent in probands: it was present in 38% of probands
with PTC versus 8% of mutation-positive relatives, and
in 23% of probands with cysteine substitution and 6%
of relatives.
In the cysteine substitution group, 6/19 (32%) as-
cending aortic replacements were performed for dissec-
tion and the remainder for aortic dilatation, whereas in
the PTC group dissection was the predominant indica-
tion (15/26 [58%]; ). In addition to aortic dis-Pp .08
section, MR was also more common in the PTC group,
with 35/54 (65%) affected, compared with 18/37 (49%)
in the cysteine substitution group ( ; differencePp .12
not significant). Spontaneous pneumothorax occurred in
8/58 (14%) individuals in the PTC group and in 4/39
(10%) individuals in the cysteine substitution group.
Both incidence figures are higher than in a clinically as-
certained heterogeneous group of patients with MFS, in
which only 11/249 (4.4%) had spontaneous pneumo-
thorax (Hall et al. 1984). Our detailed presentation of
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the clinical data for mutation-specific subgroups should
enable their inclusion in future meta-analyses of larger
patient cohorts.
Discussion
FBN1mutations have been associated with a broad spec-
trum of phenotypes, ranging from single connective-tissue
manifestations, such as isolated EL (Kainulainen et al.
1994; Lonnqvist et al. 1994), to lethal neonatalMFS (Mi-
lewicz and Duvic 1994; Putnam et al. 1996). In this article
on PTC mutations and in our previous work on in-frame
internal deletions (Liu et al. 1996, 1997, 2001) and cys-
teine substitutions (Schrijver et al. 1999), we have pre-
sented extensive studies integrating data on mutation,
transcript, and protein and clinical phenotypes. Distinct
mutation-type–specific profiles have been established at
the transcript and protein level. It now appears that it
may also be possible to subdivide MFS and other type 1
fibrillinopathies clinically, depending on the type of FBN1
mutation present. Although no specific manifestation or
set of features are diagnostic for a particular subtype, the
relative risk for specific organ involvement shows some
statistically significant differences.
Here, we report the detection of 34 FBN1 nonsense
or frameshift (PTC) mutations, 32 of which are unique
and 2 of which are recurrent. The 34 probands and 26
mutation-positive family members were studied to assess
the clinical and biochemical characteristics of this mu-
tation category. Phenotypes in our study participants
showed a range of features. On clinical grounds alone,
22/31 (71%) of probands for whom complete clinical
data were available met the revised diagnostic criteria for
MFS (De Paepe et al. 1996), when the FBN1 mutation
was not included as a criterion. If imaging studies to look
for dural ectasia and protrusio acetabuli had been per-
formed, the number of participants meeting clinical cri-
teria for MFS might have been higher (De Paepe et al.
1996; Rose et al. 2000). Age at ascertainment is clearly
important. With the median proband age of 38 years,
only two of the nine informative probands who did not
meet criteria were children who may not yet express di-
agnostic cardiovascular manifestations.
To assess the effects of the various PTC mutations on
mutant mRNA stability, we performed FBN1 mRNA
quantitation. Eight samples were studied by RT-PCR
and mutation-specific restriction digestion of the am-
plicon after a low number of PCR cycles (Schrijver et
al. 1999). In all individuals studied by this method,
mutant transcript levels were decreased, which suggests
that mutant mRNA is preferentially degraded. In ad-
dition, two FBN1 SNPs were analyzed in 10 individuals,
and, in each case, transcript levels of one allele were
reduced. Since the alleles were distinguished by SNPs
unrelated to the mutation, however, the mutant allele
could only be inferred.
Cellular recognition and degradation of mRNA that
contains premature termination codons is a process
whereby potentially harmful effects of truncated pro-
teins may be limited (Culbertson 1999; Frischmeyer
and Dietz 1999). This RNA surveillance or nonsense-
mediated mRNA decay (NMD) pathway controls the
effects of transcription errors, aberrant pre-mRNA
splicing, and nonproductive rearrangements in the im-
mune system. In human genetic diseases, NMD di-
rectly impacts the pathological effects of PTC muta-
tions. PTC mutations make up ∼25% of recognized
spontaneous disease-causing mutations in hundreds of
human genes. The effectiveness of NMD on PTC-con-
taining transcripts is highly relevant to the postulated
mechanism of disease. Rapid decay of mutant tran-
scripts leads to a loss-of-function phenotype, as first
described in recessive b-thalassemia (Baserga and Benz
1992), while synthesis of truncated proteins may have
a dominant negative effect—for example, in the ade-
nomatous polyposis coli gene (APC [MIM 175100]),
leading to dominant familial polyposis coli. On the
other hand, a truncated protein may restore partial
function and, therefore, the reduction of NMD may
have a beneficial effect, as, for example, in CFTR. Re-
garding the mechanism of NMD, recent studies sup-
port a direct connection between RNA splicing and
NMD (Le Hir et al. 2001). An intron introduced
within the 3′ UTR at a certain distance downstream of
the termination codon will target a normal mRNA for
NMD (Thermann et al. 1998). Introns are not abso-
lutely required for occurrence of decay, however, as was
demonstrated in the HEXA gene. Thus, sequences in
cis may also play a role (Rajavel and Neufeld 2001).
Cytoplasmic translation is a necessary component of the
NMD pathway (Thermann et al. 1998).
For FBN1 mutations, preferential degradation of
transcripts containing premature stop codons has been
described, with mutant transcript levels ranging from
2%–28%, compared with the normal transcript (Dietz
et al. 1993a, 1993b; Aoyama et al. 1994; Karttunen et
al. 1998; Halliday et al. 1999). Normal transcript levels
have only rarely been associated with a PTC mutation;
examples include a nonsense mutation in exon 24 (Kart-
tunen et al. 1998) and a frameshift in exon 65, the 3′-
most exon (Nijbroek et al. 1995). The latter finding is
expected, since PTCs in the final exon do not interfere
with mRNA stability. Early studies had suggested that
lowmutant transcript levels are associated with amilder
phenotype (Dietz et al. 1993a; Aoyama et al. 1994).
More recently, however, a 7% level of mutant transcript
and near absence of immunohistological staining of fi-
brillin 1 in cultured fibroblasts were reported for an
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individual with an inherited R529X mutation who had
severe aortic and skeletal manifestations (Montgomery
et al. 1998). A reported individual with severe MFS and
an R1541X mutation had mutant mRNA of 2% com-
pared with the transcript of the normal allele (Hewett
et al. 1994; Halliday et al. 1999). These observations
throw doubt on the hypothesis that mutant mRNA lev-
els in cultured cells are the major determinants of the
clinical and biochemical consequences of FBN1 PTC
mutations.
In pulse-chase protein studies, null mutations, or total
lack of mutant transcripts, would lead to reduced fi-
brillin synthesis and deposition of only normal fibrillin
1, albeit in reduced amounts. This scenario is compat-
ible with protein group I, characterized by fibrillin
synthesis at 50% of control values (2 SD; range
35%–70%) and proportional reduction of deposition
(Aoyama et al. 1994, 1995). This protein phenotype
was identified in only 4 of the 28 probands we studied.
The majority of fibrillin 1 truncation mutations in the
present study were classified as protein phenotype II,
with fibrillin synthesis at 50% of control values (2
SD; range 35%–70%) and severely reduced deposition
(!2 SD of control values; !35%). Attempts to establish
a correlation between mutant mRNA (MT) levels and
protein groups in the 14 samples studied for both pa-
rameters revealed no significant results. The 13 samples
in protein group II were associated with MT levels from
(1) mild ( ), to (2) intermediate ( ), and (3)np 4 np 7
severe reduction ( ). The one group I sample wasnp 2
associated with level 3, as expected.
The mechanism by which PTC mutations exert their
effect on extracellular fibrillin monomers and their in-
corporation into microfibrils is not entirely clear. The
existence of putative truncated proteins has been diffi-
cult to prove. Because of NMD of mutant transcripts,
they are expected to be made at low abundance. Al-
though western blotting and immunoprecipitation ex-
periments have failed, we have previously published ev-
idence of a putative truncated protein of ∼60 kD
isolated from the medium of a group II fibroblast culture
after enrichment on an immunoaffinity column (see fig.
6 of Aoyama et al. 1994). We subsequently identified a
FBN1mutation, 4177delG in exon 33, leading to a stop
codon in exon 34 after a stretch of missense codons, in
this sample (FB751; table 1). Although this mutation
would predict a truncated protein of∼150 kD, we found
a ∼60-kD product that might reflect degradation, either
during the isolation procedure or because of protein
instability and intra- or extracellular proteolysis. This
finding points to yet another variable—namely, that the
location of the stop codon may not be indicative of the
ultimate size of the mutant product and, hence, of its
putative biological activity.
Among 41 probands with PTC mutations reported
by others, there are two recurrent and 35 unique mu-
tations, a total of 14 nonsense and 23 frameshift mu-
tations (Dietz et al. 1993a; Nijbroek et al. 1995; Wang
et al. 1997; Montgomery et al. 1998; Halliday et al.
1999; Guo et al. 2001; Loeys et al. 2001; Pepe et al.
2001; Tiecke et al. 2001). We included only 19 true
PTC mutations from the study by Loeys et al. (2001),
excluding those cases listed under “frameshift” that
have in-frame deletions or insertions or that lead to
skipping of in-frame exons. It is remarkable that the
ratio of nonsense to frameshift mutations is very con-
sistent, with 14/23 in the literature and 13/20 in our
cases. The most common recurrent PTC mutation is
2471GrA in the exon 2 donor splice site. It represents
a CrT transition at a CpG mutational hotspot on the
antisense strand. As a consequence of this mutation,
exon 2 is skipped, which causes a frameshift and PTC.
Of the five unrelated individuals with this mutation, the
first one (MS8) reported (Dietz et al. 1993a) had classic
and severe manifestations at age 29 years. Three sub-
sequent individuals with the same mutation had no EL
but had major aortic and minor skeletal involvement at
ages 39, 41, and 52 (Halliday et al. 1999; Guo et al.
2001; Loeys et al. 2001). We assume that the individual
listed as “del ex 2” by Loeys et al. (2001) had this same
mutation, because the methods used would not have
detected a genomic deletion of this exon. In our proband
FB1075 and in her sibling, the same 2471GrA mu-
tation was identified. Both individuals lack EL and have
relatively mild skeletal symptoms (table 2). The amount
of fibroblast cDNA that was amplified from the mutant
allele, as compared with the normal allele, was 16%
for MS8 (Dietz et al. 1993a) and 9.9% for the 41-year-
old patient reported by Guo et al. (2001). Pulse-chase
analysis of proband MS8 revealed fibrillin synthesis of
50.7% and matrix deposition of 25.1% (Aoyama et al.
1994). In the patient reported by Guo et al. (2001),
pulse-chase analysis revealed synthesis of 41% and dep-
osition of !5% of that in normal controls. Without
quantitation, Halliday et al. (1999) reported reduced
synthesis and reduced deposition in all four individuals
with PTC studied by pulse-chase analysis, including the
2471GrA mutation carrier.
Comparison of our clinical data (table 2) with the
that from 41 patients with FBN1 PTC mutations re-
ported in the literature is limited to features that have
been consistently reported. Our most striking find-
ing—that is, that EL is present in only 32% (18/57) of
subjects—is corroborated by the frequency of 15/41
(37%) reported in the literature, when we interpret
“major criterion in the ocular system” (Loeys et al.
2001) as indicating the presence of EL. Although major
criteria in the cardiovascular system were reported in
37/41 (90%) individuals, we recorded ascending aortic
dilation and/or dissection in only 44/57 (77%) of par-
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ticipants who were evaluated for both features. This
difference may be explained by most published cases
being in probands, whereas 43% of our study popu-
lation were secondarily ascertained mutation-positive
relatives. When we consider only the probands, the fre-
quency is 28/34 (82%).
In an effort to define mutation-type–specific clinical
subgroups, we compared extensive clinical data on 60
study participants (table 2) to a large group of subjects
with type 1 fibrillinopathy due to cysteine substitutions
(Schrijver et al. 1999). The PTC-associated phenotype
emerges as a distinguishable clinical entity. Whereas
large-joint hypermobility ( ), scoliosis, and aorticP ! .01
dissection were more common in the PTC population,
EL ( ) and RD ( ) were strikingly less fre-P ! .001 P ! .01
quent than in the cysteine-substitution group.
Comparison of the protein phenotypes demonstrates
that the preponderance (75%) of probands with PTC
mutations have markedly reduced extracellular fibrillin
deposition with reduced synthesis. In contrast, 76% of
individuals with cysteine substitutions had normal levels
of fibrillin synthesis and markedly reduced matrix dep-
osition. In this group, newly synthesized fibrillin may
be sequestered intracellularly, since secretion was de-
layed (Schrijver et al. 1999). These comparisons rep-
resent a first step in understanding the differential mo-
lecular pathology of type 1 fibrillinopathies.
In conclusion, our study provides the first compre-
hensive genotype-phenotype correlation in individuals
with PTC mutations in FBN1. The new pathogenic in-
sights about this mutation category will allow more-
precise assessment of the clinical prognosis and poten-
tially will lead to tailored patient management. For
example, PTC mutation carriers may not meet clinical
criteria of MFS, and the absence of EL in the majority
of patients with PTC may delay diagnosis. Yet, these
patients are at high risk for aortic dissection and mitral
valve insufficiency. They must be monitored closely for
these life-threatening cardiovascular complications. The
risk for EL is distinctly lower than the 60% usually
quoted for patients withMFS (GeneTestsWeb site). This
risk figure was derived by studying heterogeneous pop-
ulations with MFS, merging higher-risk groups (with
FBN1 cysteine substitutions and in-frame exon skipping
mutations or deletions) with the lower-risk PTC group.
Therefore, FBN1 mutation testing and/or fibrillin pro-
tein phenotyping performed in persons suspected of
having a type 1 fibrillinopathy may assist in assignment
to a mutation-type–specific subgroup for individualized
prognosis and management.
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